Ziltivekimab

Ziltivekimab is a monoclonal antibody designed for the treatment of cardiovascular disease. It is currently under development by Corvidia Therapeutics, a subsidiary of Novo Nordisk. Ziltivekimab targets and neutralizes interleukin-6 (IL-6), a cytokine that plays a key role in the inflammatory response associated with atherosclerosis and other cardiovascular diseases.

Mechanism of Action

Ziltivekimab is a monoclonal antibody that binds to IL-6, preventing it from interacting with its receptor and initiating the inflammatory response. By inhibiting the action of IL-6, ziltivekimab may reduce inflammation and slow the progression of cardiovascular disease.

Clinical Trials

Ziltivekimab is currently in Phase 2b clinical trials for the treatment of patients with high-risk atherosclerosis and elevated levels of high-sensitivity C-reactive protein (hsCRP), a marker of inflammation. Preliminary results from these trials have shown that ziltivekimab can significantly reduce levels of hsCRP and IL-6 in patients with cardiovascular disease.

Potential Applications

In addition to its potential use in treating cardiovascular disease, ziltivekimab may also have applications in other diseases characterized by chronic inflammation, such as rheumatoid arthritis and psoriasis. However, further research is needed to confirm these potential uses.

See Also

• Monoclonal antibodies
• Interleukin-6
• Cardiovascular disease
• Atherosclerosis
• Rheumatoid arthritis
• Psoriasis

References

‎